Pfizer sues Ranbaxy to halt generic Lipitor
NEW YORK Pfizer has filed a lawsuit against Ranbaxy Laboratories in an attempt to block it from marketing a generic version of its best-selling drug Lipitor, according to published reports.
The suit filed by Pfizer in the U.S. District Court in Delaware claims Ranbaxy’s generic would infringe two patents covering the process for making Lipitor that don’t expire until July 2016.
Lipitor had sales of $12.7 billion in 2007.
Separately, Pfizer filed another suit against Ranbaxy citing the same patents in order to extend the exclusivity of Caduet, a combination of Lipitor and hypertension drug Norvasc. Caduet had 2007 sales of $568 million.
ScriptPro robotic dispensing adopted in two Haggen locations
BELLINGHAM, Washington Haggen Food & Pharmacy has added ScriptPro’s robotic dispensing devices to two of its stores, one in Ferndale and the other in Barkley Village, according to published reports.
The system automatically selects a prescription vial, counts tablets or capsules into the vial and labels it with patient, drug and dosing information.
“This system offers many advantages for our customers,” said Andrew Charter, vice president of pharmacy at Haggen Inc. “It is better than partially automated systems in providing accurately counted doses. Most importantly, it frees up our pharmacists to spend more time answering the questions of customers rather than counting pills or making labels.”
Eli Lilly, Sanofi-Aventis partner to market Cialis
BRDIGEWATER, N.J. Sanofi-Aventis has agreed to help Eli Lilly market its impotency drug Cialis, according to CNN. Financial terms were not disclosed.
Lilly gained full rights to the medicine at the beginning of 2007, when it bought the drug from ICOS for $2.3 billion.
Cialis had worldwide sales of $1.1 billion in 2007, compared with its main competitor Pfizer’s Viagra, which saw sales of $1.76 billion.